T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia.
Ibrutinib improved proliferative fitness, attenuated senescence-associated features and SASP output in paired patient and direct-exposure assays, and enhanced CAR T-cell expansion in an ibrutinib-resistant CLL model.